20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Strata Critical Medical, Inc. (SRTA) operates in the MEDICAL CARE FACILITIES industry and is headquartered in New York, United States with about 327 employees. Its market capitalization is roughly $393 million. In the fiscal year ended 2025-12-31, SRTA reported $197M in revenue and $41M in net income.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical.
Interactive charts & full statements → Open the SRTA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $256M | $197M | $249M | $225M | $146M | $51M | $23M | $31M |
| Gross Profit | $53M | $41M | $59M | $42M | $22M | $11M | $2M | $5M |
| Gross Margin % | 20.6% | 20.9% | 23.7% | 18.7% | 15.2% | 20.8% | 9.9% | 15.1% |
| Operating Income (EBIT) | ($20M) | ($22M) | ($34M) | ($68M) | ($54M) | ($24M) | ($10M) | ($12M) |
| Operating Margin % | -8.0% | -11.3% | -13.6% | -30.2% | -36.6% | -47.7% | -44.2% | -37.0% |
| Net Income | $40M | $41M | ($27M) | ($56M) | ($27M) | ($40M) | ($10M) | ($11M) |
| Net Margin % | 15.7% | 21.0% | -11.0% | -24.9% | -18.7% | -79.3% | -43.4% | -34.7% |
| EBITDA | ($9M) | ($6M) | ($22M) | ($50M) | ($22M) | ($43M) | ($10M) | ($11M) |
| Earnings Per Share (EPS) | $0.49 | $0.50 | $-0.35 | $-0.76 | $-0.38 | $-0.57 | $-0.81 | $-1.47 |
| Shares Outstanding (M) | 86M | 82M | 77M | 74M | 71M | 70M | 13M | 7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $73M | $67M | $67M | $49M | $71M | $54M | $54M | $75M |
| Gross Profit | $15M | $14M | $12M | $12M | $18M | $12M | $13M | $20M |
| Gross Margin % | 21.0% | 20.9% | 17.5% | 23.6% | 25.1% | 22.1% | 23.2% | 26.5% |
| Operating Income (EBIT) | ($5M) | ($3M) | ($6M) | ($6M) | ($5M) | ($8M) | ($8M) | ($4M) |
| Operating Margin % | -7.5% | -4.4% | -9.6% | -11.4% | -7.0% | -14.0% | -15.4% | -4.7% |
| Net Income | ($11M) | $2M | ($9M) | $57M | ($4M) | ($3M) | ($10M) | ($2M) |
| Net Margin % | -14.5% | 3.2% | -13.2% | 116.5% | -5.3% | -6.4% | -18.0% | -2.6% |
| EBITDA | ($2M) | $1M | ($1M) | ($8M) | ($2M) | ($2M) | ($8M) | ($1M) |
| Earnings Per Share (EPS) | $-0.12 | $0.02 | $-0.11 | $0.70 | $-0.05 | $-0.04 | $-0.12 | $-0.03 |
| Shares Outstanding (M) | 86M | 90M | 82M | 82M | 81M | 80M | 79M | 78M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($31M) | ($49M) | ($3M) | ($32M) | ($37M) | ($16M) | ($11M) | ($10M) |
| Capital Expenditures (CapEx) | $13M | $11M | $33M | $2M | $1M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($44M) | ($60M) | ($36M) | ($34M) | ($38M) | ($16M) | ($11M) | ($11M) |
| FCF Margin % | -17.1% | -30.4% | -14.3% | -15.3% | -25.9% | -31.5% | -47.8% | -35.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $6M | $4M | ($8M) | ($32M) | ($3M) | $0M | $0M | $6M |
| Capital Expenditures (CapEx) | $2M | $5M | $2M | $3M | $3M | $3M | $5M | $10M |
| Free Cash Flow (FCF) | $3M | ($2M) | ($10M) | ($35M) | ($6M) | ($3M) | ($5M) | ($4M) |
| FCF Margin % | 4.8% | -2.9% | -15.4% | -70.9% | -8.2% | -6.2% | -9.2% | -4.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $333M | $325M | $257M | $295M | $325M | $336M | $18M | $278M |
| Cash & Cash Equivalents | $16M | $31M | $18M | $28M | $41M | $3M | $12M | $1M |
| Total Liabilities | $53M | $46M | $35M | $61M | $51M | $45M | $7M | $273M |
| Total Debt (Short + Long-Term) | $1M | $1M | $3M | $5M | $3M | $0M | $2M | $0M |
| Total Shareholders' Equity | $279M | $279M | $222M | $234M | $274M | $291M | $11M | $5M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SRTA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms